Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected Patients

2003 ◽  
Vol 21 (18) ◽  
pp. 3447-3453 ◽  
Author(s):  
Magid Herida ◽  
Murielle Mary-Krause ◽  
Régis Kaphan ◽  
Jacques Cadranel ◽  
Isabelle Poizot-Martin ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Potential Role ◽  
Hospital Database ◽  
Highly Active ◽  
Immunodeficiency Virus ◽  
French Hospital ◽  
French Hospital Database ◽  
Age And Sex

Purpose: To determine incidence of non–AIDS-defining cancers (NADC) in HIV–infected patients before (P1) and during (P2) the use of highly active antiretroviral therapy (HAART) relative to that observed in the French general population (FGP) of the same age and sex. Patients and Methods: Sex- and age-adjusted NADC standardized incidence ratios (SIR), with FGP as reference, were estimated in 1992 to 1995 (P1) and in 1996 to 1999 (P2) in a French Hospital Database on HIV prospective hospital cohort study. Results: NADCs were diagnosed in 260 patients during P1 and 391 patients during P2 among the 77,025 patients included in the database between January 1, 1992, and December 31, 1999. Estimated incidence of all cancers was higher in HIV-infected men than in FGP during both periods (P1 SIR = 2.36 and P2 SIR = 1.91). No excess of cancers was observed among HIV-infected women in either period. Incidence of all cancers did not change from P1 to P2 in either sex (SIR = 0.96 for men and 1.00 for women). In contrast, incidence of Hodgkin’s disease (HD) was higher than in FGP in both sexes and both periods and increased in P2 as compared with P1; incidence of lung cancer was higher in both sexes during P2. Conclusion: Relative to FGP, the overall incidence of NADCs was increased in HIV-infected men but not in women and did not differ between P1 and P2. Only HD was much more common in HIV infection, and the potential role of HAART on HD cannot be excluded.

Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV

AIDS ◽  
2004 ◽  
Vol 18 (15) ◽  
pp. 2029-2038 ◽  
Author(s):  
Sophie Grabar ◽  
Isabelle Kousignian ◽  
Alain Sobel ◽  
Philippe Le Bras ◽  
Jacques Gasnault ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Hospital Database ◽  
Highly Active ◽  
Clinical Responses ◽  
French Hospital ◽  
French Hospital Database

Immune-Based Therapies for the Management of HIV Infection: Highly Active Antiretroviral Therapy and Beyond

2000 ◽  
Vol 13 (6) ◽  
pp. 515-532
Author(s):  
Aimee F. Ansari ◽  
Joseph V. Etzel
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Potential Role ◽  
Opportunistic Infections ◽  
Normal Function ◽  
Highly Active ◽  
Immunodeficiency Virus ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Improve Patient

The widespread use of highly active antiretroviral therapy (HAART) has had a significant impact on reducing the incidence of opportunistic infections in patients with the Acquired Immunodeficiency Syndrome (AIDS) and reducing the overall morbidity and mortality associated with this disease. However, the use of HAART is often associated with adverse effects, significant drug interactions, high cost and the emergence of viral resistance in a significant percentage of treatment recipients. In addition, the clinical efficacy of HAART in terms of viral eradication appears to be limited due to the presence of reservoirs of latent virus within HAART-experienced patients. Because of these and other limitations associated with antiretroviral therapies, new therapeutic strategies are being developed to restore the normal function of the immune system and improve patient outcomes. The purpose of this article is to review some of the more promising investigational immune-based therapies and their potential role in the management of Human Immunodeficiency Virus infection.

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy

Blood ◽  
2001 ◽  
Vol 98 (8) ◽  
pp. 2339-2344 ◽  
Author(s):  
Caroline Besson ◽  
Aicha Goubar ◽  
Jean Gabarre ◽  
Willy Rozenbaum ◽  
Gilles Pialoux ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Large Population ◽  
Highly Active ◽  
Primary Brain Lymphoma ◽  
Before And After ◽  
French Hospital ◽  
French Hospital Database ◽  
Improvement In Survival ◽  
Second Period

Abstract HIV infection is associated with a high incidence of AIDS-related lymphomas (ARLs). Since the use of highly active antiretroviral therapy (HAART), the incidence of AIDS-defining illnesses has decreased, leading to a significant improvement in survival of HIV-infected patients. The consequences of HAART use on ARL are under debate. This study compared the incidence and the characteristics of ARL before and after the use of HAART in a large population of HIV-infected patients in the French Hospital Database on HIV (FHDH) and particularly in 3 centers including 145 patients with proven lymphoma. Within the FHDH, the incidence of systemic ARL has decreased between 1993-1994 and 1997-1998, from 86.0 per 10 000 to 42.9 per 10 000 person-years (P < 10−30). The incidence of primary brain lymphoma has also fallen dramatically between the periods, from 27.8 per 10 000 to 9.7 per 10 000 person-years (P < 10−11). The analysis of 145 cases of ARL in 3 hospitals showed that known HIV history was longer in the second period than in the first period among patients with systemic ARL (98 versus 75 months; P < .01). Patients had a higher number of CD4 cells at diagnosis during the second period (191 versus 63/μL, P = 10−3). Survival of patients with systemic ARL also increased between the periods (from 6 to 20 months; P = .004). Therefore, the profile of ARL has changed since the era of HAART, with a lower incidence of systemic and brain ARL. The prognosis of systemic ARL has improved.

scholarly journals Highly Active Antiretroviral Therapy Normalizes the Function of Progenitor Cells in Human Immunodeficiency Virus–Infected Patients

1998 ◽  
Vol 178 (5) ◽  
pp. 1299-1305 ◽  
Author(s):  
Susanne Dam Nielsen ◽  
Annette Kjær Ersbøll ◽  
Lars Mathiesen ◽  
Jens Ole Nielsen ◽  
John‐Erik Stig Hansen
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Progenitor Cells ◽  
Highly Active Antiretroviral Therapy ◽  
Highly Active ◽  
Immunodeficiency Virus
Sign in / Sign up

Export Citation Format

Share Document